Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06157177
Other study ID # PMMSS-01
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date November 15, 2023
Est. completion date November 15, 2025

Study information

Verified date December 2023
Source Primus Pharmaceuticals
Contact S Sodhi
Phone 205-202-0739
Email simi@illumination.health
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn if a modification to metaxalone 640 mg can reduce low back and leg pain. The participants will be 18 to 80 years old, healthy with newly occurring back or leg pain. The main question aims to compare a group taking active treatment and a group taking a look-alike substance containing no active treatment. All participants will answer questions on Day 1, before treatment, and on 7-day after treatment, about: - Amount and quality of pain - Interference with physical activity - Interference with sleep


Description:

Double-blind, randomized, placebo-controlled, multi-center study of metaxalone 640 mg plus standard of care for patients with acute lumbo sacral musculoskeletal conditions with spinal stenosis and sciatica. Participants will be randomized 1:1. Following the initial pilot-study a second study will randomize a larger population of patients with appropriate power.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date November 15, 2025
Est. primary completion date November 15, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - No clinically significant conditions impacting quality or quantity of pain - Baseline Numeric Pain Scale = 6 - Capable of answering text or email survey reminders - Low back pain with or without sciatica Exclusion Criteria: - Current use of other skeletal relaxants - Current use of other pain relievers - Current use of cimetidine or monoamine oxidase inhibitors

Study Design


Intervention

Drug:
Metaxalone 640 mg Oral Tablet
Metaxalone 640 mg used for the treatment of discomforts associated with acute, musculoskeletal pain.

Locations

Country Name City State
United States Northern Virginia Center for Arthritis Annandale Virginia
United States East Alabama Arthritis Center Auburn Alabama
United States Arthritis and Osteoporosis Center Aventura Florida
United States William Sunshine, MD Boca Raton Florida
United States Robert Levin, MD Clearwater Florida
United States Jayashree Sinha, MD 1 Clovis New Mexico
United States Heritage Rheumatology & Arthritis Care Colleyville Texas
United States 5. CZ Rheumatology Coral Springs Florida
United States Carolina Rheumatology Fayetteville North Carolina
United States Integrative Rheumatology of South Texas Harlingen Texas
United States 4. Palm Beach Rheumatology and Wellness Jupiter Florida
United States Family Arthritis Center Loxahatchee Groves Florida
United States Arthritis and Rheumatology Center of South Florida Margate Florida
United States Southwest Research Group Mesquite Texas
United States DFW Rheumatology Red Oak Texas
United States Arthritis and Rheumatic Care Center South Miami Florida
United States Ohio Arthritis and Osteoporosis Center of Southwest Ohio Springboro Ohio
United States Arthritis Research and Treatment Center Stockbridge Georgia
United States Sean Wollaston, MD Valley Village California
United States Southern Ohio Rheumatology Wheelersburg Ohio

Sponsors (2)

Lead Sponsor Collaborator
Primus Pharmaceuticals Illumination Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of Numeric Pain Scale Change from Baseline in low back pain and leg pain as measured by the Numeric Pain Rating Scale (NPRS) at Day 7 Day 1 to Day 7
See also
  Status Clinical Trial Phase
Recruiting NCT04795284 - Biomechanical Parameters of Gait in Patients With Symptomatic Lumbar Spinal Stenosis and Healthy Elderly.
Recruiting NCT04066296 - Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine Phase 2
Active, not recruiting NCT05114135 - TLIF Osteo3 ZP Putty Study (Also Known as the TOP Fusion Study) N/A
Recruiting NCT06075862 - Balance Amongst Patients With Lumbar Spinal Stenosis
Recruiting NCT06057428 - Activity Levels Amongst Patients With Lumbar Spinal Stenosis
Recruiting NCT05527145 - Spinal Stenosis and Listhesis Treated With Percutaneous Interspinous Spacer: a Non-surgical Trial N/A
Recruiting NCT01902979 - The Spinal Stenosis Pedometer and Nutrition e-Health Lifestyle Intervention (SSPANLI) Trial N/A
Completed NCT00749073 - The Vertos MILD™ Preliminary Patient Evaluation Study N/A
Completed NCT00527527 - Chiropractic Dosage for Lumbar Stenosis Phase 2
Completed NCT00405691 - Safety and Effectiveness Study of the TOPS System, a Total Posterior Arthroplasty Implant Designed to Alleviate Pain Resulting From Moderate to Severe Lumbar Stenosis Phase 3
Completed NCT03194607 - Quantitative Evaluation of Motor Function Before and After Surgery for Degenerative Lumbar Spinal Stenosis
Recruiting NCT06034405 - Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Completed NCT06079580 - Patients With Lumbar Spinal Stenosis With Balance Disorder
Recruiting NCT05523388 - Role of Spinal Load in the Pathophysiology of Lumbar Spinal Stenosis
Completed NCT04587401 - The Effects of Anesthesia on Cerebral Perfusion in Patients With High Blood Pressure N/A
Completed NCT04563793 - Postmarket Outcomes Study for Evaluation of the Superion™ Spacer
Suspended NCT03381677 - Pedicle Osteotomy for Stenosis Trial N/A
Completed NCT02258672 - Preoperative Rehabilitation for Patients Undergoing Surgery for Lumbar Spinal Stenosis N/A
Completed NCT02260401 - Long Term Outcomes of Lumbar Epidural Steroid Injections for Spinal Stenosis N/A
Completed NCT01994512 - Swedish Spinal Stenosis Study N/A